Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Raw Materials (2023 - 2024)

Tarsus Pharmaceuticals has reported Raw Materials over the past 2 years, most recently at $2.5 million for Q1 2024.

  • Quarterly results put Raw Materials at $2.5 million for Q1 2024, changed N/A from a year ago — trailing twelve months through Mar 2024 was $2.5 million (changed N/A YoY), and the annual figure for FY2023 was $2.5 million, changed.
  • Raw Materials for Q1 2024 was $2.5 million at Tarsus Pharmaceuticals, roughly flat from $2.5 million in the prior quarter.
  • Over the last five years, Raw Materials for TARS hit a ceiling of $2.5 million in Q4 2023 and a floor of $2.5 million in Q4 2023.